Revival Health Inc. Announces 9 Mil FDA EUA Authorized COVID-19 Rapid At-home Tests

Available December 2021

Revival Health Inc. (Revival), a leading global medical device manufacturer, announced the availability of over 9 million units per month of the EUA authorized COVID-19 rapid at-home tests. The company has stepped up production to produce over 9 million tests in December, 10 million in January and up to 20 million in February. The COVID-19 Antigen Home Test provides:

  • Easy and Affordable
  • Highly Accurate Nasal Swab Test
  • Quick Results in 15 minutes
  • Safe for children as young as 2 years old
  • For use with and without symptoms

The COVID-19 Antigen Home Test is a simple nasal swab test which will be available for purchase without prescription.  The test is authorized for self-testing by individuals aged 14 years and older, or with adult-collected nasal swabs from children as young as 2 years old.  Uniquely, the test is authorized for use as a single test with or without symptoms in contrast to other home tests which require two tests within a two-to-three-day period.

“We are investing heavily and pulling out all the stops to get Americans maximum protection as we face this new Omicron COVID variant through the holiday season. It is our mission to make healthcare more affordable, accessible, and easy to use. Our development and investments in COVID-19 testing moves us one step closer to this achievement,” states Jenny Yang, Chief Revenue Officer at Revival Health.

The test will be available for shipping as soon as December 20, 2021.

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

The Evolut ™ FX+ TAVR system leverages market-leading valve performance with addition of larger windows to facilitate coronary access
The study was an analysis of AstraZeneca’s Phase 2 52-Week clinical trial of tralokinumab in patients with Idiopathic Pulmonary Fibrosis (IPF). The patient data from the trial was processed with Brainomix’s e-Lung tool. The tool is uniquely powered by the weighted reticulovascular score (WRVS), a novel biomarker that incorporates reticular opacities and vascular structures of the lung.
“Since the algorithm for matching patients with donors is changing across for all organs, this was a prime time to better understand whether transplant team decisions to accept a donated organ varied by patient race and gender,” she said. “We wanted to understand how the process of receiving a transplant after listing varied by race and gender, and the combination of the two, so that steps can be taken to make that process more equitable," said Khadijah Breathett, MD.
The Mount Sinai study found that primary care physicians’ approach reflects a dearth of evidence-based guidance for lung cancer screening shared decision-making in patients with complex comorbidities
This is the first ever transplantation of a genetically engineered porcine kidney into a living human recipient.

By using this website you agree to accept Medical Device News Magazine Privacy Policy

Exit mobile version